BioTime (BTX) Closes on $9 Million Financing
6/10/2013 7:34:32 AM
More...
|
BioTime (BTX) Closes on $9 Million Financing
6/7/2013 9:37:34 AM
More...
|
BioTime (BTX) to Raise $9 Million in Registered Direct Offering
6/4/2013 10:24:21 AM
More...
|
BioTime (BTX) Announces Results of Vote at Special Meeting of Shareholders
5/23/2013 10:28:11 AM
More...
|
BioTime (BTX) CEO Dr. Michael West to Present at University of Southern California Minisymposium: Musculoskeletal Development and Repair
5/20/2013 7:16:11 AM
More...
|
BioTime (BTX) Appoints Franklin Berger to Board of Directors
5/15/2013 7:51:08 AM
More...
|
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist
5/13/2013 10:07:01 AM
More...
|
BioTime (BTX) Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments
5/13/2013 7:14:05 AM
More...
|
BioTime (BTX) and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research
5/7/2013 10:48:09 AM
More...
|
BioTime (BTX) Enters Into Worldwide License Agreement With University of California, Los Angeles (UCLA) to Develop Therapy for the Treatment of Stroke
4/19/2013 9:50:12 AM
More...
|
|